To date, there are no approved vaccines or antiviral treatments for human norovirus, the leading cause of acute gastroenteritis outbreaks worldwide with more than 685 million infections each year.

CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of ...

CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted ...

BOTHELL, Wash., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (COCP). (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical ...

Add Yahoo as a preferred source to see more of our stories on Google. Almost every winter, norovirus outbreaks spread throughout the U.S. Norovirus – or what some call the “stomach flu” – can happen ...

Stopping viruses before they strike is a key challenge in public health. A research team led by Associate Professor Li Dan ...

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...

Norovirus—the “winter vomiting bug”—is responsible for millions of cases of vomiting and diarrhea each year.

Seaweed may be a popular food item, but it has certain properties which have the ability to create a shield within the human body, effectively ...

We might be near the end of winter, but the spread of norovirus shows little sign of slowing down. The number of people in hospital with the winter vomiting bug has hit a record h ...

As winter break starts to wind down for most college students, this means that returning to school for the spring semester has officially arrived. There may have been a lot of things that students ...

CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infections Company to present Phase 1 data and updates from ongoing Phase 1b study ...